<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chlordiazepoxide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chlordiazepoxide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Chlordiazepoxide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9243" href="/d/html/9243.html" rel="external">see "Chlordiazepoxide: Drug information"</a> and <a class="drug drug_patient" data-topicid="11598" href="/d/html/11598.html" rel="external">see "Chlordiazepoxide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F49519386"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risks from concomitant use of benzodiazepines and opioids:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Abuse, misuse, and addiction:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of benzodiazepines, including chlordiazepoxide, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing chlordiazepoxide and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Dependence and withdrawal reactions:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The continued use of benzodiazepines, including chlordiazepoxide, may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of chlordiazepoxide after continued use may precipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue chlordiazepoxide or reduce the dosage.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1004788"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Benzodiazepine</span></li></ul></div>
<div class="block dop drugH1Div" id="F149558"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="681d778e-2c1e-46c3-9264-d477867f0a71">Anxiety</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety:</b>
<b>Note:</b> Use of chlordiazepoxide as an anxiolytic has been replaced by newer agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19588367','lexi-content-ref-22275849']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19588367','lexi-content-ref-22275849'])">Ref</a></span>). Children ≥6 years and Adolescents: Oral: Usual dose: 5 mg 2 to 4 times daily; may increase to 10 mg 2 to 3 times daily in some patients. Pediatric patients may have variable response; begin with the lowest dose and slowly titrate.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51084655"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no pediatric-specific dosage adjustments provided in the manufacturer’s labeling; in adult patients, dosage adjustment suggested.</p></div>
<div class="block dohp drugH1Div" id="F51084656"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, chlordiazepoxide undergoes hepatic metabolism and should be used with caution.</p></div>
<div class="block doa drugH1Div" id="F149543"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9243" href="/d/html/9243.html" rel="external">see "Chlordiazepoxide: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Reduce dose or avoid use in patients receiving opioids or with significant chronic disease (eg, respiratory compromise) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32107742','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32107742','lexi-content-ref-Manu.1'])">Ref</a></span>). Avoid use in patients with a history of substance use, misuse of medications, or depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3aebc5bd-197b-462c-a687-896607ebce9b">Alcohol withdrawal syndrome, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alcohol withdrawal syndrome, treatment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Withdrawal will progress at different rates in some patients; flexibility in dosing and duration is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). Regimens vary and depend on withdrawal history, degree of current withdrawal symptoms, blood alcohol concentration, and whether the patient is treated inpatient or in the ambulatory setting. Many facilities only treat alcohol withdrawal in the ambulatory setting if Clinical Institute Withdrawal Assessment for Alcohol (CIWA-AR) score is ≤15 and there is no history of withdrawal seizures or delirium tremens (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1','lexi-content-ref-33224688']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1','lexi-content-ref-33224688'])">Ref</a></span>). The following are 2 suggested regimens.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Symptom-triggered regimen:</i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend symptom-triggered dosing for patients who score &gt;15 on the CIWA-AR, revised scale (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hoffman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hoffman.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 25 to 100 mg as needed per institution-specific protocol until appropriate sedation achieved; dose and frequency determined by withdrawal symptom severity using a validated severity assessment scale, such as the CIWA-AR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<i>Example regimen (Holt 2023):</i></p>
<p style="text-indent:-2em;margin-left:12em;">Day 1: <b>Oral</b>: 50 mg every 6 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">Day 2: <b>Oral</b>: 50 mg every 8 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">Day 3: <b>Oral</b>: 50 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:12em;">Day 4: <b>Oral</b>: 50 mg once at bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Fixed regimen: </i></b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts recommend fixed-dose regimens for patients at risk for mild withdrawal (CIWA-AR ≤15), particularly in an ambulatory setting where CIWA-AR scores cannot be reliably administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>). In addition to scheduled doses shown in the example regimen below, provide up to 5 additional as-needed 50 mg doses to be used over the 4-day treatment period for breakthrough symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Holt.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Holt.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Day 1: <b>Oral: </b>50 mg every 4 to 6 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 2: <b>Oral: </b>50 mg every 8 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 3: <b>Oral: </b>50 mg every 12 to 24 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Day 4: <b>Oral: </b>25 mg every 12 to 24 hours, then discontinue chlordiazepoxide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32511109','lexi-content-ref-Holt.1','lexi-content-ref-28006997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32511109','lexi-content-ref-Holt.1','lexi-content-ref-28006997'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e83bc66-3e6e-49b3-ab21-449ee2b4f882">Anxiety disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety disorders (adjunctive therapy or monotherapy) (alternative agent): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Generally used short-term for symptom relief until preferred therapy (eg, serotonin reuptake inhibitor) is effective (eg, 4 to 6 weeks, followed by tapering). Long-term low-dose therapy (eg, 5 mg/day) may be considered in select patients when other treatments are ineffective or poorly tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-25081580','lexi-content-ref-35900161'])">Ref</a></span>). Use with caution in patients with posttraumatic stress disorder; benzodiazepines may worsen symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VaDoD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VaDoD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Usual range: <b>Oral: </b>5 to 25 mg 2 to 4 times daily; increase gradually based on response and tolerability; patients with mild to moderate symptoms generally respond to total daily doses ≤40 mg. Maximum dose: 100 mg/day in divided doses.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Unless safety concerns require a more rapid withdrawal, gradually taper to detect reemerging symptoms and minimize rebound and withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low or moderate dose, no concerns for benzodiazepine use disorder</b>
<b>:</b> Taper total daily dose by 20% to 25% every week based on response and tolerability (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Craske.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Craske.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Extended or high-dose therapy, or suspected benzodiazepine use disorder:</b> Taper total daily dose by approximately 25% every 1 to 2 weeks based on response, tolerability, and individual patient factors (taper increments will be limited by available dosage forms) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). Reduce dose more rapidly in the beginning, and slow the dose reduction as the taper progresses because earlier stages of withdrawal are easier to tolerate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21714826','lexi-content-ref-VA.DoD.2'])">Ref</a></span>). The optimal duration and taper increment will vary; up to 6 months may be necessary for some patients on higher doses, and a taper rate of 50% every week may be tolerated in some patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.1','lexi-content-ref-VA.DoD.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991215"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, the following recommendations have been used by some clinicians:</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥10 mL/minute: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;10 mL/minute: Administer 50% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Peritoneal dialysis: Administer 50% of dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988420"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, chlordiazepoxide undergoes hepatic metabolism and should be used with caution.</p></div>
<div class="block adr drugH1Div" id="F149503"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Edema, syncope</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Abnormal electroencephalogram, ataxia, confusion, drowsiness, drug-induced extrapyramidal reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Change in libido, menstrual disease</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Constipation, nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Agranulocytosis, bone marrow depression</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic: Hepatic insufficiency, jaundice</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Paradoxical reaction</p></div>
<div class="block coi drugH1Div" id="F149520"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to chlordiazepoxide or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F149500"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines; risk may be increased in adolescent/pediatric patients, geriatric patients, or patients with a history of alcohol use disorder or psychiatric/personality disorders (Mancuso 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sleep-related activities: Hazardous sleep-related activities such as sleep-driving, cooking and eating food, and making phone calls while asleep have been noted with benzodiazepines (Dolder 2008).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Avoid use in patients with depression because of concerns about worsening mood symptoms, particularly if suicidal risk may be present, except for acute or emergency situations (eg, acute agitation, status epilepticus) (Craske 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Porphyria: Use with caution in patients with porphyria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disease: Reduce dose or avoid use in patients with respiratory disease, including chronic obstructive pulmonary disease or sleep apnea. Benzodiazepines may cause significant respiratory depression.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Debilitated patients: Use with caution in debilitated patients; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects, including ataxia and over-sedation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Avoid use; if used, use with caution in older adults; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects, including ataxia and over-sedation. Older adult patients may be at an increased risk of death with use; risk has been found highest within the first 4 months of use in older adult dementia patients (Jennum 2015; Saarelainen 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury (Nelson 1999).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Use with caution in children; active metabolites with extended half-lives may lead to delayed accumulation and adverse effects, including ataxia and over-sedation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Abuse, misuse, and substance use disorder: Counsel patients at increased risk on proper use and monitor for signs and symptoms of abuse, misuse, and substance use disorder. Institute early treatment or refer patients in whom substance use disorder is suspected. Limit dosages and durations to the minimum required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dependence and withdrawal reactions: Some patients may develop a protracted withdrawal syndrome lasting &gt;12 months; may be difficult to differentiate withdrawal symptoms from reemergence or continuation of symptoms for which benzodiazepines were prescribed. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tolerance: Chlordiazepoxide is a long half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance does not develop to the anxiolytic effects (Vinkers 2012). Chronic use of this agent may increase the perioperative benzodiazepine dose needed to achieve desired sedative effect.</p></div>
<div class="block foc drugH1Div" id="F149512"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 25 mg</p></div>
<div class="block geq drugH1Div" id="F149496"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F149523"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (chlordiazePOXIDE HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.35 - $19.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.40 - $21.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.43 - $22.33</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866295"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 10 mg, 25 mg</p></div>
<div class="block csi drugH1Div" id="F149579"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-IV</p></div>
<div class="block sts drugH1Div" id="F149531"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F49640426"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2016%2F012249s049lbl.pdf%23page%3D8&amp;token=CKPde%2BCmbyo2vs9FV6Wx18PxiTEqet6h4B9NQKtnRzlCYd%2FysRseOFNwbFZG9mtIGupFVd1oMAQt8OSaG9mGeDteIOt3riQmNiN%2F29GeW9dZ0Cts3xmwulWj72f0Qtcv&amp;TOPIC_ID=118515" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/012249s049lbl.pdf#page=8</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53565996"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Management of anxiety disorders, short-term relief of symptoms of anxiety or preoperative apprehension and anxiety (FDA approved in ages ≥6 years and adults); management of withdrawal symptoms of acute alcoholism (FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F149587"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">ChlordiazePOXIDE may be confused with chlorproMAZINE or chlorothiazide</p>
<p style="text-indent:-2em;margin-left:4em;">Librium may be confused with Librax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Chlordiazepoxide is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older due to risk of abuse, misuse, physical dependence, and addiction. In addition, older adults have an increased risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents with benzodiazepine use and slower metabolism of long-acting benzodiazepines (eg, chlordiazepoxide). However, benzodiazepines may be appropriate in the elderly when used for seizure disorders, rapid eye movement sleep behavior disorder, benzodiazepine or ethanol withdrawal, severe generalized anxiety disorder, or periprocedural anesthesia (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F149572"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F149505"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alizapride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Azelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin.  Management: Use caution if coadministering blonanserin and CNS depressants; dose reduction of the other CNS depressant may be required. Strong CNS depressants should not be coadministered with blonanserin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine at lower doses in patients already receiving CNS depressants.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: CNS Depressants may enhance the CNS depressant effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of ChlordiazePOXIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Monitor for respiratory depression, hypotension, and other toxicities if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of ChlordiazePOXIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dose reduction of daridorexant and/or any other CNS depressant may be necessary. Use of daridorexant with alcohol is not recommended, and the use of daridorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexmedeTOMIDine: CNS Depressants may enhance the CNS depressant effect of DexmedeTOMIDine.  Management: Monitor for increased CNS depression during coadministration of dexmedetomidine and CNS depressants, and consider dose reductions of either agent to avoid excessive CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Difelikefalin: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May increase the serum concentration of ChlordiazePOXIDE.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxylamine: CNS Depressants may enhance the CNS depressant effect of Doxylamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroPERidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (eg, opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: CNS Depressants may enhance the CNS depressant effect of Flunarizine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam.  Management: Reduce the dose of CNS depressants when combined with flunitrazepam and monitor patients for evidence of CNS depression (eg, sedation, respiratory depression). Use non-CNS depressant alternatives when available.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: ChlordiazePOXIDE may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider a decrease in the CNS depressant dose, as appropriate, when used together with hydroxyzine. Increase monitoring of signs/symptoms of CNS depression in any patient receiving hydroxyzine together with another CNS depressant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ilaprazole: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kava Kava: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: May enhance the CNS depressant effect of CNS Depressants. Management: Dosage adjustments of lemborexant and of concomitant CNS depressants may be necessary when administered together because of potentially additive CNS depressant effects. Close monitoring for CNS depressant effects is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May enhance the sedative effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: Benzodiazepines may enhance the CNS depressant effect of Methadone.  Management: Clinicians should generally avoid concurrent use of methadone and benzodiazepines when possible; any combined use should be undertaken with extra caution.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce the usual dose of CNS depressants by 50% if starting methotrimeprazine until the dose of methotrimeprazine is stable. Monitor patient closely for evidence of CNS depression.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OLANZapine: Benzodiazepines may enhance the adverse/toxic effect of OLANZapine.  Management: Monitor closely for hypotension, respiratory or central nervous system depression, and bradycardia if olanzapine is combined with benzodiazepines. Use of parenteral benzodiazepines with IM olanzapine is not recommended.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olopatadine (Nasal): May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: CNS Depressants may enhance the CNS depressant effect of Opioid Agonists.  Management: Avoid concomitant use of opioid agonists and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxybate Salt Products: Benzodiazepines may enhance the CNS depressant effect of Oxybate Salt Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procarbazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: CNS Depressants may enhance the adverse/toxic effect of Ropeginterferon Alfa-2b. Specifically, the risk of neuropsychiatric adverse effects may be increased.  Management: Avoid coadministration of ropeginterferon alfa-2b and other CNS depressants. If this combination cannot be avoided, monitor patients for neuropsychiatric adverse effects (eg, depression, suicidal ideation, aggression, mania).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teduglutide: May increase the serum concentration of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valerian: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants. No such dose change is recommended for women. Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to the use of zuranolone with other CNS depressants or alcohol. If combined, consider a zuranolone dose reduction and monitor patients closely for increased CNS depressant effects.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F58001496"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use. Pregnancy testing is recommended before treating acute alcohol withdrawal symptoms (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety should be individualized (BAP [McAllister-Williams 2017]); avoid the use of benzodiazepines for the treatment of anxiety disorders in patients planning to become pregnant (Larsen 2015).</p></div>
<div class="block pri drugH1Div" id="F11228990"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Chlordiazepoxide crosses the human placenta and fetal serum concentrations are similar to those in the mother (Stirrat 1974).</p>
<p style="text-indent:0em;margin-top:2em;">In utero exposure to benzodiazepines has the potential to cause harm to the fetus. Teratogenic effects have been observed in some studies; however, a clear association has not been reported and additional data are needed (Bellantuono 2013; Freeman 2018; Grigoriadis 2019; Noh 2022; Szpunar 2022; Tinker 2019; Wikner 2007). Exposure to a benzodiazepine late in pregnancy may cause neonatal sedation (hypotonia, lethargy, respiratory depression) and/or symptoms of neonatal withdrawal (feeding difficulties, hyperreflexia, inconsolable crying, irritability, restlessness, tremors). Data related to long-term effects on neurodevelopment are inconclusive (Chen 2022; Radojčić 2017; Sundbakk 2022; Wang 2022). Newborns exposed to chlordiazepoxide in utero should be monitored for feeding problems, respiratory depression, sedation, and withdrawal.</p>
<p style="text-indent:0em;margin-top:2em;">Treatment for alcohol withdrawal may be considered for pregnant patients with at least moderate symptoms (CIWA-Ar scores ≥10) (ASAM 2020). The short-term use of a long-acting benzodiazepine may be used in pregnant patients requiring treatment of acute alcohol withdrawal symptoms (WHO 2014); however, the use of shorter-acting benzodiazepines is preferred in patients at risk for preterm delivery or when treatment is needed during the third trimester (ASAM 2020). Although recommendations vary by guideline, the use of chlordiazepoxide may be considered when treating pregnant patients (BAP [McAllister-Williams 2017]; SOGC [Graves 2020]; WFSBP/IAWMH [Thibaut 2019]). Monitor newborns for fetal alcohol spectrum disorders in addition to benzodiazepine intoxication (ASAM 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Therapy for anxiety during pregnancy should be individualized. Untreated or inadequately treated psychiatric illness may lead to poor adherence to prenatal care and adverse pregnancy outcomes (ACOG 2008). Benzodiazepines are not preferred when pharmacologic treatment for anxiety disorders is needed during pregnancy (BAP [McAllister-Williams 2017]; Larsen 2015) and when a benzodiazepine is needed, the use of chlordiazepoxide is not preferred. If possible, avoid scheduled doses of benzodiazepines in the month prior to delivery to reduce the risk of withdrawal symptoms in the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to chlordiazepoxide is ongoing. Health care providers are encouraged to enroll patients exposed to chlordiazepoxide during pregnancy in the National Pregnancy Registry for Psychiatric Medications (1-866-961-2388).</p></div>
<div class="block mopp drugH1Div" id="F53565977"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Respiratory and cardiovascular status (including orthostasis); mental status; paradoxical reactions (eg, excitement, stimulation, acute rage); if used for ethanol withdrawal, signs/symptoms of ethanol withdrawal</p></div>
<div class="block pha drugH1Div" id="F149499"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Long-acting benzodiazepine (Griffin 2013). Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the CNS, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization. Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors (Vinkers 2012).</p></div>
<div class="block phk drugH1Div" id="F149519"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Duration of action: Classified as a long-acting benzodiazepine; classification based on benzodiazepines with half-life &gt;40 hours (Griffin 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3.3 L/kg (Schwartz 1971)</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 96% (Baskin 1982)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic to desmethyldiazepam (active and long-acting), desmethylchlordiazepoxide, and demoxepam (Baskin 1982; Schwartz 1971).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent: 24 to 48 hours; demoxepam 14 to 95 hours (Schwartz 1971)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 0.5 to 2 hours (Baskin 1982)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (1% to 2% unchanged; 3% to 6% as metabolite)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F149525"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Apo-chlordiazepoxide</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Calmoden | Chlordiazepox | Chlordiazepox aps | Chlordiazepox cox | Chlordiazepox dc | Chlordiazepox kent | Chlordiazepoxide | Chlordiazepoxide hydrochloride roche | Librium | Tropium</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Oasil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Chlordiazepoxide | Corlium | Litamin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Librium | Tensinyl</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Librium</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Librium | Reliberan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Balance | Peast c</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Clozepam | Liberty</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Psicodex</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Librium</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Kalmocaps</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Benpine | Chlordiazepoxide</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Librium</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nova-pam</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Chlordiazepox hydrochloride | Chlordiazepoxide | Chlordiazepoxide HCL | Librium</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Lentotran</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Librium</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo-chlordiazepoxide | Benpine | Klorpo</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Benpine | Chlordiazepoxide | Cozep | Epoxide | Lazep | Librium | Minoxide | Tranadon S | Vapine</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Anaten | Chlordiazepoxide | Dipoxido | E chun | Honcalm | Libmin | Librium | Lipolin | Livarium | Peace | Sugent | Suil | Zunchin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Librium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin No. 92: Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001-1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32511109">
<a name="32511109"></a>American Society of Addiction Medicine (ASAM). The ASAM clinical practice guideline on alcohol withdrawal management. <i>J Addict Med</i>. 2020:14(3S)(suppl 1):1-72. doi:10.1097/ADM.0000000000000668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/32511109/pubmed" id="32511109" target="_blank">32511109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007:125.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders.<i> World J Biol Psychiatry</i>. 2023;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6152590">
<a name="6152590"></a>Baskin SI, and Esdale A, “Is Chlordiazepoxide the Rational Choice Among Benzodiazepines?” <i>Pharmacotherapy</i>, 1982, 2(2):110-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/6152590/pubmed" id="6152590" target="_blank">6152590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23044244">
<a name="23044244"></a>Bellantuono C, Tofani S, Di Sciascio G, Santone G. Benzodiazepine exposure in pregnancy and risk of major malformations: a critical overview. <i>Gen Hosp</i>
<i>Psychiatry</i>. 2013;35(1):3-8. doi:10.1016/j.genhosppsych.2012.09.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/23044244/pubmed" id="23044244" target="_blank">23044244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36413366">
<a name="36413366"></a>Chen VC, Wu SI, Lin CF, Lu ML, Chen YL, Stewart R. Association of prenatal exposure to benzodiazepines with development of autism spectrum and attention-deficit/hyperactivity disorders. <i>JAMA Netw Open</i>. 2022;5(11):e2243282. doi:10.1001/jamanetworkopen.2022.43282<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/36413366/pubmed" id="36413366" target="_blank">36413366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Chartwell.1">
<a name="Chartwell.1"></a>Chlordiazepoxide [prescribing information]. Congers, NY: Chartwell RX LLC; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Solco.1">
<a name="Solco.1"></a>Chlordiazepoxide [prescribing information]. Cranbury, NJ: Solco Healthcare; January 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: Management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 19. 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32107742">
<a name="32107742"></a>Currow DC, Agar MR. Benzodiazepine prescribing in people with chronic obstructive pulmonary disease: clinical considerations. <i>Drugs Aging</i>. 2020;37(4):263-270. doi:10.1007/s40266-020-00756-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/32107742/pubmed" id="32107742" target="_blank">32107742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18998740">
<a name="18998740"></a>Dolder CR, Nelson MH. Hypnosedative-induced complex behaviours: incidence, mechanisms and management. <i>CNS Drugs.</i> 2008;22(12):1021-1036. doi:10.2165/0023210-200822120-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/18998740/pubmed" id="18998740" target="_blank">18998740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29958100">
<a name="29958100"></a>Freeman MP, Góez-Mogollón L, McInerney KA, et al. Obstetrical and neonatal outcomes after benzodiazepine exposure during pregnancy: results from a prospective registry of women with psychiatric disorders. <i>Gen Hosp Psychiatry</i>. 2018;53:73-79. doi:10.1016/j.genhosppsych.2018.05.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/29958100/pubmed" id="29958100" target="_blank">29958100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gordon.1">
<a name="Gordon.1"></a>Gordon AJ. Identification and management of unhealthy alcohol use in the perioperative period. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32900457">
<a name="32900457"></a>Graves L, Carson G, Poole N, et al. Guideline no. 405: screening and counselling for alcohol consumption during pregnancy. <i>J Obstet Gynaecol Can</i>. 2020;42(9):1158-1173.e1. doi:10.1016/j.jogc.2020.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/32900457/pubmed" id="32900457" target="_blank">32900457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-359214">
<a name="359214"></a>Greenblatt DJ, Shader RI, MacLeod SM, Sellers EM. Clinical pharmacokinetics of chlordiazepoxide. <i>Clin Pharmacokinet</i>. 1978;3(5):381-394. doi:10.2165/00003088-197803050-00004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/359214/pubmed" id="359214" target="_blank">359214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23789008">
<a name="23789008"></a>Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. <i>Ochsner J</i>. 2013;13(2):214-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/23789008/pubmed" id="23789008" target="_blank">23789008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31294935">
<a name="31294935"></a>Grigoriadis S, Graves L, Peer M, et al. Benzodiazepine use during pregnancy alone or in combination with an antidepressant and congenital malformations: systematic review and meta- analysis. <i>J Clin Psychiatry.</i> 2019;80(4):18r12412. doi:10.4088/JCP.18r12412<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/31294935/pubmed" id="31294935" target="_blank">31294935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hoffman.1">
<a name="Hoffman.1"></a>Hoffman RS, Weinhouse GL. Management of moderate and severe alcohol withdrawal syndromes. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holt.1">
<a name="Holt.1"></a>Holt SR, Tetrault JM. Alcohol withdrawl: Ambulatory management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 14, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32063496">
<a name="32063496"></a>Hosseinzadeh Zoroufchi B, Doustmohammadi H, Mokhtari T, Abdollahpour A. Benzodiazepines related sexual dysfunctions: a critical review on pharmacology and mechanism of action.<i> Rev Int Androl</i>. 2021;19(1):62-68. doi:10.1016/j.androl.2019.08.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/32063496/pubmed" id="32063496" target="_blank">32063496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19588367">
<a name="19588367"></a>Ipser JC, Stein DJ, Hawkridge S, Hoppe L. Pharmacotherapy for anxiety disorders in children and adolescents. <i>Cochrane Database Syst Rev.</i> 2009;(3):CD005170. doi:10.1002/14651858.CD005170.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/19588367/pubmed" id="19588367" target="_blank">19588367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11773648">
<a name="11773648"></a>Iqbal MM, Sobhan T, Ryals T, et al, "Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant," <i>Psychiatr Serv</i>, 2002, 53(1):39-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/11773648/pubmed" id="11773648" target="_blank">11773648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26342397">
<a name="26342397"></a>Jennum P, Baandrup L, Ibsen R, et al. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: A population-based register study. <i>Eur Neuropsychopharmacol.</i> 2015;25(11):1906-1913. doi:10.1016/j.euroneuro.2015.08.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/26342397/pubmed" id="26342397" target="_blank">26342397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33830479">
<a name="33830479"></a>Kelty E, Terplan M, Greenland M, Preen D. Pharmacotherapies for the treatment of alcohol use disorders during pregnancy: time to reconsider? <i>Drugs</i>. 2021;81(7):739-748. doi:10.1007/s40265-021-01509-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/33830479/pubmed" id="33830479" target="_blank">33830479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22275849">
<a name="22275849"></a>Kodish I, Rockhill C, Varley C. Pharmacotherapy for anxiety disorders in children and adolescents. <i>Dialogues Clin Neurosci</i>. 2011;13(4):439-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/22275849/pubmed" id="22275849" target="_blank">22275849</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21714826">
<a name="21714826"></a>Lader M. Benzodiazepines revisited--will we ever learn? <i>Addiction</i>. 2011;106(12):2086-2109. doi: 10.1111/j.1360-0443.2011.03563.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/21714826/pubmed" id="21714826" target="_blank">21714826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28. doi:10.1111/acps.12479<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15460178">
<a name="15460178"></a>Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. <i>Pharmacotherapy</i>. 2004;24(9):1177-1185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/15460178/pubmed" id="15460178" target="_blank">15460178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28440103">
<a name="28440103"></a>McAllister-Williams RH, Baldwin DS, Cantwell R, et al; endorsed by the British Association for Psychopharmacology. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. <i>J Psychopharmacol.</i> 2017;31(5):519-552. doi:10.1177/0269881117699361<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/28440103/pubmed" id="28440103" target="_blank">28440103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33224688">
<a name="33224688"></a>Moore TA. Ambulatory detoxification in alcohol use disorder and opioid use disorder. <i>Ment Health Clin</i>. 2020;10(6):307-316. doi:10.9740/mhc.2020.11.307<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/33224688/pubmed" id="33224688" target="_blank">33224688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24364635">
<a name="24364635"></a>Muncie HL Jr, Yasinian Y, Oge' L. Outpatient management of alcohol withdrawal syndrome. <i>Am Fam Physician</i>. 2013;88(9):589-595.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/24364635/pubmed" id="24364635" target="_blank">24364635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10519733">
<a name="10519733"></a>Nelson J, Chouinard G. Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. <i>Can J Clin Pharmacol</i>. 1999;6(2):69-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/10519733/pubmed" id="10519733" target="_blank">10519733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35235572">
<a name="35235572"></a>Noh Y, Lee H, Choi A, et al. First-trimester exposure to benzodiazepines and risk of congenital malformations in offspring: a population-based cohort study in South Korea. <i>PLoS Med</i>. 2022;19(3):e1003945. doi:10.1371/journal.pmed.1003945<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/35235572/pubmed" id="35235572" target="_blank">35235572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.1">
<a name="Park.1"></a>Park TW. Benzodiazepine use disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28259732">
<a name="28259732"></a>Radojčić MR, El Marroun H, Miljković B, et al. Prenatal exposure to anxiolytic and hypnotic medication in relation to behavioral problems in childhood: a population-based cohort study. <i>Neurotoxicol Teratol.</i> 2017;61:58-65. doi:10.1016/j.ntt.2017.02.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/28259732/pubmed" id="28259732" target="_blank">28259732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29143367">
<a name="29143367"></a>Saarelainen L, Tolppanen AM, Koponen M, et al. Risk of death associated with new benzodiazepine use among persons with Alzheimer disease: A matched cohort study. <i>Int J Geriatr Psychiatry.</i> 2018;33(4):583-590. doi:10.1002/gps.4821<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/29143367/pubmed" id="29143367" target="_blank">29143367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8046805">
<a name="8046805"></a>Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. <i>JAMA</i>. 1994;272(7):519-523.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/8046805/pubmed" id="8046805" target="_blank">8046805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5129365">
<a name="5129365"></a>Schwartz MA, Postma E and Gaut Z, “Biological Half-Life of Chlordiazepoxide and its Metabolite, Demoxepam, in Man,” <i>J Pharm Sci</i>, 1971, 60(10):1500-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/5129365/pubmed" id="5129365" target="_blank">5129365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28006997">
<a name="28006997"></a>Soyka M, Kranzler HR, Hesselbrock V, Kasper S, Mutschler J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Substance Use Disorders. Guidelines for biological treatment of substance use and related disorders, part 1: alcoholism, first revision.<i> World J Biol Psych</i>iatry. 2017;18(2):86-119. doi:10.1080/15622975.2016.1246752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/28006997/pubmed" id="28006997" target="_blank">28006997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4859397">
<a name="4859397"></a>Stirrat GM, Edington PT, Berry DJ. Letter: transplacental passage of chlordiazepoxide. <i>Br Med J</i>. 1974;2(5921):729. doi:10.1136/bmj.2.5921.729-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/4859397/pubmed" id="4859397" target="_blank">4859397</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36520439">
<a name="36520439"></a>Sundbakk LM, Gran JM, Wood ME, Handal M, Skurtveit S, Nordeng H. Association of prenatal exposure to benzodiazepines and Z-hypnotics with risk of attention-deficit/hyperactivity disorder in childhood. <i>JAMA Netw Open</i>. 2022;5(12):e2246889. doi:10.1001/jamanetworkopen.2022.46889<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/36520439/pubmed" id="36520439" target="_blank">36520439</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35909254">
<a name="35909254"></a>Szpunar MJ, Freeman MP, Kobylski LA, et al. Risk of major malformations in infants after first-trimester exposure to benzodiazepines: results from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications. <i>Depress Anxiety</i>. 2022;39(12):751-759. doi:10.1002/da.23280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/35909254/pubmed" id="35909254" target="_blank">35909254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30632868">
<a name="30632868"></a>Thibaut F, Chagraoui A, Buckley L, et al. WFSBP and IAWMH guidelines for the treatment of alcohol use disorders in pregnant women. <i>World J Biol</i>
<i>Psychiatry</i>. 2019;20(1):17-50. doi:10.1080/15622975.2018.1510185<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/30632868/pubmed" id="30632868" target="_blank">30632868</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30891943">
<a name="30891943"></a>Tinker SC, Reefhuis J, Bitsko RH, et al; National Birth Defects Prevention Study. Use of benzodiazepine medications during pregnancy and potential risk for birth defects, National Birth Defects Prevention Study, 1997-2011. <i>Birth Defects Res</i>. 2019;111(10):613-620. doi:10.1002/bdr2.1497<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/30891943/pubmed" id="30891943" target="_blank">30891943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VaDoD.1">
<a name="VaDoD.1"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal.pdf</a>. Updated June 2017. Accessed March 9, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VA.DoD.2">
<a name="VA.DoD.2"></a>US Department of Veterans Affairs/US Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. <a href="https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/sud/VADoDSUDCPG.pdf</a>. Published August 2021. Accessed May 12, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22536226">
<a name="22536226"></a>Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective gaba(a) receptor modulators? <i>Adv Pharmacol Sci</i>. 2012;2012:1-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/22536226/pubmed" id="22536226" target="_blank">22536226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35367514">
<a name="35367514"></a>Wang X, Zhang T, Ekheden I, et al. Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: a systematic review.<i> Neurosci Biobehav Rev.</i> 2022;137:104647. doi:10.1016/j.neubiorev.2022.104647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/35367514/pubmed" id="35367514" target="_blank">35367514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17894421">
<a name="17894421"></a>Wikner BN, Stiller CO, Bergman U, et al. Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: neonatal outcome and congenital malformations. <i>Pharmacoepidemiol Drug Saf</i>. 2007;16(11):1203-1210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/chlordiazepoxide-pediatric-drug-information/abstract-text/17894421/pubmed" id="17894421" target="_blank">17894421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guidelines for the identification and management of substance use and substance use disorders in pregnancy. <a href="https://www.ncbi.nlm.nih.gov/books/NBK200701/" target="_blank">https://www.ncbi.nlm.nih.gov/books/NBK200701</a>. Published 2014.</div>
</li></ol></div><div id="topicVersionRevision">Topic 118515 Version 189.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
